Adjunctive metformin therapy in type 1 diabetes in pregnancy: insights from an Australian cohort
Abstract
Metformin has gained attention as a potential adjunct therapy in pregnant women with type 1 diabetes mellitus (T1DM), although evidence is limited. We present the first reported experience of metformin use in pregnant women living with T1DM who used continuous glucose monitoring to monitor glycaemic outcomes. In our multicentre case series, metformin use was associated with an increased time in range and reduced glycaemic variability, supporting potential use in pregnant women with T1DM.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.